Late August and September 2026 disclosures detail Tinavi's workforce shift and M&A, Broncus's commercial milestones, and MicroPort MedBot's trading halt.
read more ›Analysis of late-August and early-September 2026 disclosures from Tinavi, Broncus Medical, and MicroPort MedBot covering M&A, approvals, and workforce data.
read more ›Eight NMPA Class III approvals, $370M+ in headline funding, and Chinese surgical robots shipping to nearly 40 countries — a review of 2025's structural shift.
read more ›Edge Medical Robotics listed on the Hong Kong Stock Exchange in late December 2025, trading under 2675.HK after a confidential IPO filing process began in August.
read more ›Surgerii's SHURUI single-port robot received CE certification under EU MDR in August 2025, followed by a $100M Series D led by Loyal Valley Capital for global expansion.
read more ›NMPA Announcement No. 63, July 2025: 10 measures to support high-end medical devices, naming surgical and rehabilitation robots as priority categories.
read more ›MicroPort MedBot's Toumai completed liver tumor resections via LEO satellite, Xiong'an to Beijing, July 2–3, 2025, with one-way latency under 60 ms per the company.
read more ›WeMed Medical's ETcath received NMPA approval March 21, 2025, becoming China's first fully domestically developed robot for percutaneous coronary intervention.
read more ›